News & Publications

 

14 March 2017

VACCINE REGIMEN INDUCED DURABLE IMMUNE RESPONSE 1 YEAR AFTER VACCINATION

Phase 1 clinical trial data published in JAMAThe Journal of the American Medical Association show that the Ebola vaccine regimen induced a durable immune response in 100 percent of healthy volunteers one year following vaccination.

Read more


 

9 March 2017

OF VACCINES, RUMOURS, AND THE SUCCESS OF IMI’S EBODAC PROJECT

When IMI’s EBODAC project started in late 2014, Ebola had already killed over 8 000 people in just a few short months, most of them in the western African nations of Liberia, Guinea and Sierra Leone. With the outbreak continuing to devastate lives across the region, fear and anxiety were rife, and rumours spread rapidly through local communities. It was against this backdrop that EBODAC set out to develop a community engagement strategy to enable a clinical trial of a promising new Ebola vaccine candidate. Thanks to the many innovative methods employed, including radio and drama shows, today the project celebrates its first big success: all of the adults in the trial have been successfully vaccinated.

Read more


 

March 2017

EBOVAC1 AND EBODAC CONSORTIA PUBLISH ANNUAL REPORT SUMMARIES

The EBOVAC1 and EBODAC consortia have published summaries of their 2016 annual reports to IMI.


 

19 April 2016

GLOBAL PUBLIC-PRIVATE PARTNERSHIP ANNOUNCES PUBLICATION OF POSITIVE PHASE 1 DATA FOR EBOLA VACCINE REGIMEN IN JAMA

A public-private partnership of some of the world’s leading health organizations today announced that data from a Phase 1 study of a preventive Ebola vaccine regimen have been published in JAMA: The Journal of the American Medical Association. The results, the first published on the vaccine regimen, suggest that the regimen was well-tolerated by healthy volunteers and immunogenic (produced an immune response). Among the findings, 100 percent of participants in the study achieved an initial antibody response to Ebola, and this response was sustained 8 months following immunization. The study was led by the Oxford Vaccine Group at the University of Oxford Department of Paediatrics and took place in the United Kingdom.

Read more


 

9 October 2015

CLINICAL TRIAL FOR NEW EBOLA VACCINE STARTS IN KAMBIA DISTRICT, SIERRA LEONE

‘EBOVAC-Salone’, a clinical trial to assess the safety and immunogenicity of a new vaccine against Ebola, has started with the vaccination of the first volunteers. The first volunteers to be vaccinated come from Kambia Town, and more volunteers from Kambia District will be enrolled in the study in stages over the course of the next few months.

Read more

These projects have received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement EBOVAC1 (grant nr. 115854), EBOVAC2 (grant nr. 115861), EBOMAN (grant nr. 115850) and EBODAC (grant nr. 115847). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and European Federation of Pharmaceutical Industries and Associations (EFPIA).
www.imi.europa.eu
Copyright © 2018 Ebovac | Terms and Conditions | WordPress development by Toast.